Evidence map›Paper›PMID 26938448›Full record

SynthesisPLoS neglected tropical diseases2016

Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review.

Johan van Griensven, Endalamaw Gadisa, Abraham Aseffa, Asrat Hailu, Abate Mulugeta Beshah, Ermias Diro

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
7.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. A case of adnexal cutaneous leishmaniasis in Washington DC.Journal of ophthalmic inflammation and infection · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Johan van GriensvenDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Endalamaw GadisaArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Abraham AseffaArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Asrat HailuSchool of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Abate Mulugeta BeshahWorld Health Organization, Addis Ababa, Ethiopia.
Ermias DiroDepartment of Internal Medicine, University of Gondar, Gondar, Ethiopia.
Armauer Hansen Research Institute · ETAddis Ababa University · ETInstituut voor Tropische Geneeskunde · BEUniversity of Gondar · ET

Funding

World Health Organization 001
6 · The paper itself

Abstract

Leishmania aethiopica is the etiological agent of cutaneous leishmaniasis (CL) in Ethiopia and can cause severe and complicated cases such as diffuse CL (DCL), mucocutaneous leishmaniasis or extensive CL, requiring systemic treatment. Despite the substantial burden, evidence-based treatment guidelines are lacking. We conducted a systematic review of clinical studies reporting on treatment outcomes of CL due to L aethiopica in order to help identify potentially efficacious medications on CL that can be taken forward for clinical trials. We identified a total of 24 records reporting on 506 treatment episodes of CL presumably due to L aethiopica. The most commonly used drugs were antimonials (n = 201), pentamidine (n = 150) and cryotherapy (n = 103). There were 20 case reports/series, with an overall poor study quality. We only identified two small and/or poor quality randomized controlled trials conducted a long time ago. There were two prospective non-randomized studies reporting on cryotherapy, antimonials and pentamidine. With cryotherapy, cure rates were 60-80%, and 69-85% with antimonials. Pentamidine appeared effective against complicated CL, also in cases non-responsive to antimonials. However, all studies suffered from methodological limitations. Data on miltefosine, paromomycin and liposomal amphotericin B are extremely scarce. Only a few studies are available on DCL. The only potentially effective treatment options for DCL seem to be antimonials with paromomycin in combination or pentamidine, but none have been properly evaluated. In conclusion, the evidence-base for treatment of complicated CL due to L aethiopica is extremely limited. While antimonials remain the most available CL treatment in Ethiopia, their efficacy and safety in CL should be better defined. Most importantly, alternative first line treatments (such as miltefosine or paromomycin) should be explored. High quality trials on CL due to L aethiopica are urgently needed, exploring group sequential methods to evaluate several options in parallel.

Indexed as

AdolescentAdultAgedAntiprotozoal AgentsChildChild, PreschoolCryotherapyEthiopiaFemaleHumansLeishmaniaLeishmaniasis, CutaneousMaleMiddle AgedProspective StudiesTreatment OutcomeAntiprotozoal Agents

Identifiers

PMID26938448
PMCPMC4777553
OpenAlexW2292265138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.